Felixvet Introduces Firocoxib Chewable Tablets for Dogs for the Control of Osteoarthritis and Postoperative Pain

Kansas City, Mo. — July 21, 2026 — Felixvet Inc. today announced the commercial availability of Firocoxib Chewable Tablets for Dogs, an FDA-approved non-steroidal anti-inflammatory drug (NSAID) indicated for the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft tissue and orthopedic surgery in dogs. Approved by the U.S. Food and Drug Administration on August 3, 2023, under ANADA 200-755, the product provides veterinarians with a trusted treatment option for both chronic and postoperative pain management.

Product Details

“Pain management is a critical component of both long-term care and postoperative recovery in dogs,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “We’re excited to bring Firocoxib Chewable Tablets to the veterinary market and provide veterinarians with an FDA-approved treatment option that supports canine comfort, mobility, and recovery.”

Firocoxib Chewable Tablets are indicated for the control of pain and inflammation associated with osteoarthritis and for the control of postoperative pain and inflammation associated with soft tissue and orthopedic surgery in dogs.

The product is available in two strengths:

• 57 mg chewable tablets 
• 227 mg chewable tablets 

Designed to support convenient administration and dosing flexibility, the tablets feature an appealing artificial meat flavor and are scored for easy and accurate dosing. The product is available in both 60-count and 180-count bottle presentations.

“Veterinarians rely on effective pain management therapies every day, whether supporting aging dogs with osteoarthritis or helping patients recover following surgery,” added Lauren Landolph. “The addition of Firocoxib Chewable Tablets reflects Felixvet’s continued commitment to providing high-quality treatment options that support better outcomes for companion animals.”

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and pet owners with high-quality treatment options across a broad range of therapeutic categories.

For additional information, please contact info@felixvet.com.

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com